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Background: The adipocytokines leptin and adiponectin have been variously associated with diabetic
microvascular complications. No comprehensive clinical data exist examining the association between
adipocytokines and the presence of these complications.
Methods: This is a systematic reviewof cross-sectional studies comparing circulating adipocytokines inpatientswith
type 2 diabetes mellitus (T2DM), with and without microvascular complications. Studies were retrieved from
MEDLINE, EMBASE, Scopus and Cochrane databases. Study quality was evaluated using a modiﬁed Newcastle–
Ottawa Scale. Meta-analysis was performed using an inverse-variance model, providing standardised mean
differences (SMD) and 95% conﬁdence intervals (CI). Heterogeneity was determined by I2 statistic.
Results:Amongst 554 identiﬁed studies, 28 were included in the review. Study quality range was 3.5–9 (maximum
11). Higher leptin levels were associated with microalbuminuria (SMD = 0.41; 95% CI = 0.14–0.67; n = 901;
p = 0.0003), macroalbuminuria (SMD = 0.68; 95% CI = 0.30–1.06; n = 406; p = 0.0004), and neuropathy
(SMD = 0.26; 95% CI = 0.07–0.44; n = 609; p = 0.008). Higher adiponectin levels were associated with
microalbuminuria (SMD = 0.55; 95% CI = 0.29–0.81, n = 274; p b 0.001), macroalbuminuria (SMD = 1.37; 95%
CI = 0.78–1.97, n = 246; p b 0.00001), neuropathy (SMD = 0.25; 95% CI = 0.14–0.36; n = 1516; p b 0.00001),
and retinopathy (SMD = 0.38; 95% CI = 0.25–0.51; n = 1306; p b 0.00001). Meta-regression suggested no
inﬂuence of bodymass index and duration of diabetes on effect size, and aweak trend in terms of age on effect size.
Discussion: Our meta-analysis suggests leptin and adiponectin levels are higher in T2DM patients with
microvascular complications. Studies were limited by cross-sectional design. Large prospective analyses are
required to validate these ﬁndings.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus (DM), a chronic progressive disease characterised
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c. This is an open access article undand mortality. In Australia, recent statistics suggest that approximately
3.61 million people are affected by diabetes mellitus, both type 1 and
type2 (Whiting, Guariguata,Weil, & Shaw, 2011). Basedon studies from
110 countries, the International Diabetes Federation (IDF) estimated
that in 2014 therewere 387million peoplewithdiabetes; this number is
expected to rise to nearly 600 million by 2035 (IDF, 2014).
Due to chronic hyperglycaemia and associated metabolic abnor-
malities, patients with DM are at an increased risk for developing
several macro- and microvascular complications (Hammes, 2003),
namely retinopathy, nephropathy and neuropathy. Retinopathy
affects approximately 25% of the population with diabetes, and is
associated with blood vessel damage in the retina, with the potential
to cause signiﬁcant, and sometimes irreversible, vision loss (Klein,er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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approximately 30% in patients with diabetes; it is associated with
vascular injury in the nephrons, affecting renal function at different
levels. Serious nephropathy can evolve into chronic kidney disease
and eventual end-stage renal disease, meaning these patients must
either enter long-term haemodialysis or require renal transplantation
(Costacou, Ellis, Fried, & Orchard, 2007). Neuropathy is associated
with vascular and neuronal damage (commonly peripheral, but also
autonomic), leading to impairment of sensation, movement or organ/
gland control. In more severe cases, impairment of sensation can
result in ulceration requiring limb amputation. Within the population
with diabetes, neuropathy has a prevalence as high as 25% (Dyck et al.,
1993; Edwards, Vincent, Cheng, & Feldman, 2008).
Whilst the clinical aspects of these microvascular complications are
well understood, their molecular mechanisms remain unclear. As type 2
diabetes mellitus (T2DM) is commonly associated with obesity, it has
been proposed that adipocytokines, which are produced by the adipose
tissue, can directly inﬂuence the pro-atherogenic and pro-inﬂammatory
environment of the vascular walls (Cha et al., 2012). Leptin and
adiponectin are the two most abundant adipocytokines, and have
previously been linked with vascular complications in patients with
T2DM (Hanai et al., 2010, 2014; Matsuda, Kawasaki, Inoue, et al., 2004;
Matsuda, Kawasaki, Yamada, et al., 2004; Stehouwer, Lambert, Donker, &
van Hinsbergh, 1997; Uckaya et al., 2000).
Leptin is a16-kDamolecule synthesisedprimarilyby theadipose tissue.
It is the chief energy regulatory hormone, acting both centrally in the
hypothalamus at the arcuate nucleus to produce sensations of satiety; and
peripherally to stimulate fatty acid oxidation and glucose disposal
(Paz-Filho et al., 2012). Furthermore, leptin has several cytokine-like
actions. Importantly, leptin shares structural homology with the interleu-
kin-6 (IL-6) molecule, which is a well-established pro-inﬂammatory
effector (Mak, Cheung, Cone, &Marks, 2006). Leptin toohas emerged as an
important inﬂammatory molecule responsible for vascular inﬂammation,
increased oxidative stress, endothelial dysfunction and proliferation of
vascular smooth muscle cells (VSMC), and resultant intimal hyperplasia
(Guzik, Marvar, Czesnikiewicz-Guzik, & Korbut, 2007).
Adiponectin is also an adipocytokine, but its function is complementary
and antagonistic to leptin (Safai et al., 2015). For instance, whilst leptin
promotes VSMC proliferation, in vitro studies indicate that adiponectin has
the inverse effect and furthermore, adiponectin has been shown to inhibit
TNF-α, an important inﬂammatorymediatorwhich facilitates cell adhesion
(Chandran, Phillips, Ciaraldi, & Henry, 2003; Okamoto et al., 2002;
Yamauchi et al., 2001). Therefore, these adipocytokines are of direct
clinical relevance to diabetic microvascular complications.
In patients with diabetes and obesity, leptin levels are increased and
adiponectin, decreased (Goldstein, Scalia,&Ma, 2009;Havel, 2004). In this
way, patients with T2DM may be exposed to an increased risk of leptin/
adiponectin axis-mediated vascular inﬂammation, and subsequent
damage leading to the development of microvascular complications
(Niswender & Magnuson, 2007; Payne, Tune, & Knudson, 2014).
Despite several studiesdemonstrating thepathophysiological association
between these adipocytokines and endothelial dysfunction (Van de Voorde,
Pauwels, Boydens, & Decaluwé, 2013), clinical data have proved heteroge-
neous, andnostudy todatehas systematically examined theevidence in this
area. Consequently, we sought to survey the literature with the aim to (1)
through a systematic review, synthesise and critically evaluatework done in
this ﬁeld and (2) through meta-analysis, clarify the results from this
literature, to determine if there is an associationbetween the adipocytokines
leptin and adiponectin, and diabetic microvascular complications.
2. Methods
2.1. Study focus and eligibility criteria
To achieve our aims, we conducted a systematic review in
accordance with the PRISMA guidelines (Preferred Reporting Itemsfor Systematic Reviews and Meta-Analyses) (Moher, Liberati, Tetzlaff,
& Altman, 2009) and sought original (observational) studies that
examined the association between circulating concentrations of
leptin, adiponectin or both (measured by any kind of assay), with
the presence or absence of diabetic microvascular complications
(retinopathy, nephropathy and neuropathy). Studies were considered
eligible for systematic review if the investigation evaluated either
concentrations of leptin or adiponectin (or both) in patients with
T2DM whom were affected by at least one microvascular complica-
tion, and compared these concentrations against patients with T2DM
without these complications.
Speciﬁc exclusion criteria were: studies not comparing two groups
of patients with T2DM (e.g. diabetic complications versus non-dia-
betic complications), studies evaluating only a cohort of patients with
type 1 diabetes, studies that did not present data that could be
interpreted as a comparison of leptin or adiponectin between patients
with and without microvascular complications, animal or cell-based
studies, and individual case reports.
The diagnosis of T2DM was made according to the American
Diabetes Association (ADA) guidelines (ADA, 2010). Further, in
accordance with these guidelines, patients with urinary albumin
excretion between 30 and 300 mg/day (or if urinary albumin
excretion between 30 and 300 μg/g creatinine) were considered to
have microalbuminuria; macroalbuminuria was deﬁned as urinary
albumin excretion N300 mg/day (or if urinary albumin excretion
N300 mg/g creatinine), and normoalbuminuria was deﬁned as
urinary albumin excretion b30 mg/day (or if urinary albumin
excretion b30 μg/g creatinine; i.e., absence of nephropathy) (Group,
2013). Diabetic retinopathy (DR) was classiﬁed as normal, non--
proliferative and proliferative according to fundoscopic exam per-
formed by an ophthalmologist. Non-proliferative DR was deﬁned
based on one or more of the following ﬁndings: exudates, microvas-
cular abnormalities, microaneurysm, or haemorrhage. Proliferative
DR was diagnosed in the presence of new vessels. For the diagnosis of
peripheral or autonomic neuropathies, we considered only validated
methods to be appropriate. Peripheral neuropathy was deﬁned as
patient reporting changes in sensations (subjectively, or objectively
by employing validated screening instruments such as the Michigan
Neuropathy Screening Instrument) (Jung, Kim, Mok, Kang, & Kim,
2014), altered clinical tests (monoﬁlament test, vibration test and
ankle reﬂex test) and/or abnormal electrophysiological studies.
Autonomic neuropathy was diagnosed by abnormal cardiovascular
reﬂex tests (Jung et al., 2012).
2.2. Units of measurement
Leptin levels were recorded as ng/mL. In order to have unit
consistency across all the studies examining adiponectin, we applied a
conversion factor of 0.03 to adiponectin results that were not reported
as μg/mL. This was determined by contacting the manufacturer of the
assay used in one study (Matsuda, Kawasaki, Inoue, et al., 2004;
Matsuda, Kawasaki, Yamada, et al., 2004) that measured the 30 kDa
form of adiponectin (personal correspondence).
2.3. Information sources and search strategy
We surveyed the MEDLINE (archives from 1966 to 2014), Scopus
(1996–2014), EMBASE (1947–2014) and Cochrane Library (1992–
2014) databases, and applied the following title/abstract terms
[“leptin” OR “adiponectin”] AND [“retinopathy” OR “nephropathy”
OR “neuropathy” OR “microvascular complication”] with no language
restriction, on the 16th of August 2014. Additionally, we manually
scanned the reference lists of eligible texts and the related articles lists
that were generated, following a database search for other potential
studies of interest. We termed these texts the “grey literature”.
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obtain full text manuscripts direct from authors and further data were
also sought direct from authors in order to ensure study eligibility.
2.4. Meta-analysis eligibility
Studies were eligible for meta-analysis if they ﬁrst satisﬁed the
criteria for systematic review and reported data speciﬁcally relating
mean leptin and/or adiponectin (serum or plasma) concentrations in
a group of patients with at least one microvascular complication
(case), against data relatingmean leptin and/or adiponectin (serum or
plasma) concentrations in a group of patients without microvascular
complications (control). Studies were excluded from meta-analysis if
the study did not speciﬁcally report leptin and/or adiponectin
concentrations in patients with and without a speciﬁc microvascular
complication (for example, a cohort comprising a mix of patients with
retinopathy, patients with nephropathy and patients with neuropa-
thy). Contact was made with authors requesting these speciﬁc data in
an attempt to include as much literature as possible.
2.5. Study selection and data extraction process
Two reviewers (AJR and VSN) independently screened the records
identiﬁed by the literature search for studies eligible for full-text review.
Both reviewers extracted data using an extraction template. Information
was compiled relating to: study design; study participants and baseline
risk factors; outcomemeasurement and assessment; patient biochemical
data (speciﬁcally of the adipocytokines of interest); statistical analysis of
results; limitations highlighted by study investigators; and limitations not
considered by investigators. For eligible cohort studies, data were
extracted from baseline evaluation. Any discrepancies were resolved
through iteration and consensus on the ﬁnal output.
2.6. Quality assessment
In addition to data extraction, two reviewers (GP-F and CAM)
independently performed a quality assessment of the studies included
following screening. As no standardised quality assessment tool exists for
investigations assessing adipocytokines in diabetic microvascular com-
plications, we modiﬁed the previously validated Newcastle–Ottawa
Quality Assessment Scale (scale widely used for quality assessment of
observational studies), to suit our aims (Wells et al., 2009). In a “star rating
system”, each included study was judged in the following areas: sample
representativeness; sample size; outcome deﬁnition and measurement;
comparability of results; outcome assessment and statisticalmethods. For
the ﬁnal scoring, the average score given by both reviewers was
calculated. A sample data extraction form and quality assessment tool is
provided (Supplementary Material A.1).
2.7. Meta-analysis
Data were ﬁrst tabulated into a format that allowed comparison of
mean leptin and adiponectin concentrations in groups of patients with
andwithoutmicrovascular complications.As leptin andadiponectin levels
can be inﬂuenced by renal insufﬁciency, we performed the adipocytokine
analysis considering levels of albuminuria: microalbuminuria versus
normoalbuminuria; macroalbuminuria versus normoalbuminuria;
macroalbuminuria versus microalbuminuria. For diabetic retinopathy,
the group analyses were: diabetic retinopathy (non-proliferative and
proliferative) versus no retinopathy; non-proliferative retinopathy versus
no diabetic retinopathy; proliferative versus non-proliferative. Neuropa-
thy was evaluated as neuropathy or no neuropathy. Tabulated outcomes
were then synthesised using the inverse-variance method, and as
adipocytokines were measured in either plasma or serum, standardised
mean differences (SMD) was used instead of mean difference. The 95%
conﬁdence interval (95% CI) was also reported. Heterogeneity wasdetermined by the Q statistic (deﬁned as the I2 statistic and its degrees of
freedom)and inconsistencypercentage (I2)wasdeﬁnedas the ratio of the
difference between the Q statistic and degrees of freedom with the Q
statistic “[(Q − df)/Q] × 100” (Higgins & Thompson, 2002). Random or
ﬁxed effects models were applied based on whether I2 was greater than
50% in each analysis. To assess any impact important confounders might
have on the effect size, we also conducted meta-regression where effect
sizes were regressed against study-level confounders, and trends were
noted giving an indication whether confounder was related to the effect
size. All statistical operations were performed in consultation with a
statistician (TN) and using the software RevMan v5.3 (The Nordic
Cochrane Centre, The Cochrane Collaboration 2012).
2.8. Sensitivity analysis
In instances of a signiﬁcant result in meta-analysis, to assess if one
particular study contributed exceptionally to the result, we performed
a leave-one-out sensitivity analysis. The meta-analysis was repeated
with the exclusion of a single study, and was repeated for all the
studies in the analysis (each time re-including the one study left out).
3. Results
3.1. Included literature
Initial database search identiﬁed 721 records, of which 167 were
duplicates (i.e. appearing in more than one searched database),
leaving 554 unique records available for abstract screening. Screening
of abstracts removed a further 509 studies. This left 45 articles for full
text review and of these, a further 17 studies were excluded for
different reasons. Overall, 28 studies (Asakawa, Tokunaga, &
Kawakami, 2001; Cha et al., 2012; Chan et al., 2004; Choe et al.,
2013; Chung, Tsai, Chang, Shin, & Lee, 2005; Dossarps et al., 2014;
Fruehwald-Schultes et al., 1999; Fujita et al., 2006; Gottsater, Ahren, &
Sundkvist, 1999; Hanai et al., 2010; Jung et al., 2012, 2014; Kato et al.,
2008; Komaba et al., 2006; Kopeisy, A. H. A., & Wasfy, 2011;
Koshimura et al., 2004; Matsuda, Kawasaki, Inoue, et al., 2004;
Matsuda, Kawasaki, Yamada, et al., 2004; Parveen & Zia Qureshi, 2013;
Pradeepa et al., 2015; Ran et al., 2010; Saito et al., 2007; Sari, Balci, &
Apaydin, 2010; Swellam, Sayed Mahmoud And, & Ali, 2009; Uckaya
et al., 2000; Wilson, Nelson, Nicolson, & Pratley, 1998; Yilmaz et al.,
2004, 2008) satisﬁed our inclusion and exclusion criteria for
systematic review, and data from 21 of those studies were eligible
for meta-analysis (Asakawa et al., 2001; Cha et al., 2012; Chan et al.,
2004; Choe et al., 2013; Chung et al., 2005; Dossarps et al., 2014;
Fruehwald-Schultes et al., 1999; Fujita et al., 2006; Hanai et al., 2010;
Jung et al., 2012, 2014; Kato et al., 2008; Komaba et al., 2006; Kopeisy
et al., 2011; Koshimura et al., 2004; Matsuda, Kawasaki, Inoue, et al.,
2004;Matsuda, Kawasaki, Yamada, et al., 2004; Parveen & Zia Qureshi,
2013; Pradeepa et al., 2015; Ran et al., 2010; Saito et al., 2007; Sari
etal., 2010;Swellametal., 2009;Uckayaetal., 2000;Wilsonetal., 1998;Yilmaz
et al., 2004, 2008) (Fig. 1). Included studies are listed in Table 1. Funnel
plots are also provided (Supplementary Fig. A.1–A.9), which are
mostly symmetrical, as an indication into the lack of publication bias.
3.2. Study characteristics
All 28 studies were cross-sectional analyses, twelve studies
assessed retinopathy (Asakawa et al., 2001; Choe et al., 2013;
Dossarps et al., 2014; Jung et al., 2014; Kato et al., 2008; Matsuda,
Kawasaki, Inoue, et al., 2004; Matsuda, Kawasaki, Yamada, et al., 2004;
Parveen & Zia Qureshi, 2013; Pradeepa et al., 2015; Sari et al., 2010;
Swellam et al., 2009; Uckaya et al., 2000; Yilmaz et al., 2004); twenty
studies assessed nephropathy (Asakawa et al., 2001; Cha et al., 2012;
Chanet al., 2004;Choe et al., 2013; Chung et al., 2005; Fruehwald-Schultes
et al., 1999; Fujita et al., 2006; Hanai et al., 2010; Jung et al., 2014; Kato
Fig. 1. PRISMA ﬂow diagram of literature search protocol.
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2004;Matsuda, Kawasaki, Inoue, et al., 2004;Matsuda, Kawasaki, Yamada,
et al., 2004; Ran et al., 2010; Saito et al., 2007; Sari et al., 2010; Swellam
et al., 2009; Wilson et al., 1998; Yilmaz et al., 2008) and eight studies
examined neuropathy (Asakawa et al., 2001; Choe et al., 2013;
Gottsater et al., 1999; Jung et al., 2012, 2014; Matsuda, Kawasaki,
Inoue, et al., 2004; Matsuda, Kawasaki, Yamada, et al., 2004; Sari et al.,
2010; Swellam et al., 2009). Nine studies assessed leptin from serum
(Asakawa et al., 2001; Chan et al., 2004; Dossarps et al., 2014;
Fruehwald-Schultes et al., 1999; Hanai et al., 2010; Jung et al., 2012,
2014; Kopeisy et al., 2011; Parveen & Zia Qureshi, 2013; Sari et al.,
2010); seven studies measured plasma leptin (Cha et al., 2012; Chung
et al., 2005; Gottsater et al., 1999; Matsuda, Kawasaki, Inoue, et al.,
2004; Matsuda, Kawasaki, Yamada, et al., 2004; Sari et al., 2010;
Uckaya et al., 2000; Wilson et al., 1998). Of the studies that assessed
adiponectin, eight studies assessed serum adiponectin (Dossarps
et al., 2014; Fujita et al., 2006; Jung et al., 2012, 2014; Kato et al., 2008;
Koshimura et al., 2004; Pradeepa et al., 2015; Saito et al., 2007) and seven
assessed plasma adiponectin (Choe et al., 2013; Matsuda, Kawasaki,
Inoue, et al., 2004; Matsuda, Kawasaki, Yamada, et al., 2004; Ran et al.,
2010; Swellam et al., 2009; Yilmaz et al., 2004, 2008) (Tables 1 and 2).
3.3. Quality assessment
Average quality assessment scores ranged from 3.5 to 9. Items #1,
3, 5 and 6 were the most reported items. These items related to
sample representativeness (#1); outcome deﬁnition and measure-ment (#3); outcome assessment (#5) and employment of appropriate
statistical methods (#6). Items #2 and #4 respectively relating to
sample size and comparability of results were variously reported.
Table 3 summarises the individual scores.
3.4. Patient proﬁle
Study population cohorts ranged from n = 30 participants to n =
1480 (Chung et al., 2005; Fruehwald-Schultes et al., 1999). Mean age of
study participants ranged from 45.9 to 70.4 years-old in case groups, and
45.8 to 67.2 years-old in control groups (Cha et al., 2012; Ran et al., 2010).
Mean patient body mass index (BMI) ranged from 23.7 to 35.8 kg/m2 in
cases (Komaba et al., 2006; Parveen & Zia Qureshi, 2013) and 23.2 to
33.7 kg/m2 in controls (Dossarps et al., 2014; Koshimura et al., 2004).
Finally, mean diabetes duration ranged from 1.31 to 18.7 years in cases
(Fruehwald-Schultes et al., 1999; Uckaya et al., 2000), and 1.2 to
13.9 years in controls (Fruehwald-Schultes et al., 1999; Uckaya et al.,
2000). These data and further details on patient risk factors are found in
the Supplementary Tables (Tables A.1, A.2, A.3 and A.4).
3.5. Meta-analysis
3.5.1. Leptin
3.5.1.1. Retinopathy. Leptin concentration was not signiﬁcantly
different in patients with diabetic retinopathy (n = 92) relative to
patients without diabetic retinopathy (n = 288) from three studies
Table 1
Details of studies included in the systematic review.
Study Year Patients
(n)
Outcome Blood medium Meta-analysis
Leptin Adiponectin
Asakawa 2000 182 Retinopathy, nephropathy, neuropathy Serum n/a *
Cha 2012 163 Nephropathy Plasma n/a *
Chan 2003 46 Nephropathy Serum n/a *
Choea 2013 693 Retinopathy, nephropathy, neuropathy n/a Plasma *
Chung 2005 1480 Nephropathy Plasma n/a *
Dossarps 2013 179 Retinopathy Serum Serum *
Fruehwald-Schultes 1999 30 Nephropathy Serum n/a *
Fujita 2006 53 Nephropathy n/a Serum
Gottsater 1999 82 Neuropathy Serum n/a
Hanai 2010 502 Nephropathy Serum n/a *
Jung 2012 142 Neuropathy Serum Serum *
Jung 2014 153 Retinopathy, nephropathy, neuropathy Serum Serum *
Kato 2008 198 Retinopathy, nephropathy n/a Serum
Komaba 2006 179 Nephropathy n/a n/r *
Kopiesy 2011 100 Nephropathy Serum n/a *
Koshimura 2004 38 Nephropathy n/a Serum *
Matsuda 2004 231 Retinopathy, nephropathy Plasma Plasma *
Matsuda 2004 105 Neuropathy n/a Plasma
Parveen 2013 86 Retinopathy Serum n/a *
Pradeepa 2014 487 Retinopathy n/a Serum *
Ran 2010 50 Nephropathy n/a Plasma *
Saito 2007 280 Nephropathy n/a Serum
Sari 2010 157 Retinopathy, nephropathy, neuropathy Plasma n/a *
Swellam 2009 179 Retinopathy, nephropathy, neuropathy n/a Plasma
Uckaya 2000 136 Retinopathy Plasma n/a *
Wilson 1999 20 Nephropathy Plasma n/a
Yilmaz 2004 74 Retinopathy n/a Plasma *
Yilmaz 2008 123 Nephropathy n/a Plasma *
n/a = not applicable; n/r = not reported.
a Only provided biochemical data for nephropathy as study examined association between adiponectin gene variants and incidence of diabetic microvascular complications.
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difference(SMD)of theeffect sizewas0.49andthe95%conﬁdence interval
(CI) ranged from −0.38 to 1.36 (p = 0.27) (Supplementary Fig. B.1).
Heterogeneity for this analysis was 91% as determined by the I2 index
(Table 4). When considering severity of retinopathy, leptin was not
signiﬁcantly different in patients with non-proliferative diabetic retinop-
athy (n = 45) compared to patients without diabetic retinopathy (n =
153) [SMD = 0.78; 95% CI = −0.70 to 2.25; p = 0.30; I2 = 93%] from
two studies (Sari et al., 2010; Uckaya et al., 2000) (Supplementary Fig. B.2,
Table 4). Leptinwasnot signiﬁcantly different in patientswithproliferative
diabetic retinopathy(n = 29)comparedtopatientswithnon-proliferative
diabetic retinopathy (n = 45) [SMD = 0.41; 95% CI = −0.11 to 0.93;
p = 0.12; I2 = 16%] from two studies (Sari et al., 2010; Uckaya et al.,
2000) (Supplementary Fig. B.3, Table 4). Leptin was not signiﬁcantly
different in patients with proliferative diabetic retinopathy (n = 29)
compared to patients without diabetic retinopathy (n = 153) [SMD =
0.91; 95%CI = −0.53 to 2.36; p = 0.21; I2 = 90%] from two studies (Sari
et al., 2010; Uckaya et al., 2000) (Supplementary Fig. B.4, Table 4).
3.5.1.2. Nephropathy. Leptin was signiﬁcantly elevated in patients with
microalbuminuria (n = 318) relative to patientswith normoalbuminuria
(n = 583) [SMD = 0.41; 95% CI = 0.14–0.67; p = 0.003; I2 = 58%]
from six studies (Cha et al., 2012; Chung et al., 2005; Fruehwald-Schultes
et al., 1999; Hanai et al., 2010; Kopeisy et al., 2011; Sari et al., 2010)
(Supplementary Fig. C.1, Table 4). A leave-one-out sensitivity analysis
conﬁrmed this result (Supplementary Fig. C.2). Leptin was signiﬁcantly
elevated in patients with macroalbuminuria (n = 157) relative to
patients with normoalbuminuria (n = 249) [SMD = 0.68; 95% CI =
0.30–1.06; p = 0.0004; I2 = 57%] from six studies (Cha et al., 2012;
Chung et al., 2005; Fruehwald-Schultes et al., 1999; Kopeisy et al., 2011;
Sari et al., 2010; Wilson et al., 1998) (Supplementary Fig. D.1, Table 4). A
leave-one-out sensitivity analysis conﬁrmed this result (Supplementary
Fig D.2). Leptin was signiﬁcantly elevated in patients with macroalbumi-
nuria (n = 137) relative to patients with microalbuminuria (n = 150)[SMD = 0.44; 95% CI = 0.20–0.68; p = 0.0003; I2 = 0%] from four
studies (Cha et al., 2012; Chung et al., 2005; Kopeisy et al., 2011; Sari et al.,
2010) (Supplementary Fig. E, Table 4).
3.5.1.3. Neuropathy. Higher leptin concentration was observed in
patients with diabetic neuropathy (n = 184) compared to patients
without neuropathy (n = 425) [SMD = 0.26; 95% CI = 0.07–0.44;
p = 0.008; I2 = 0%] from four studies (Asakawa et al., 2001; Jung
et al., 2012, 2014; Sari et al., 2010) (Supplementary Fig. F, Table 4).
3.5.2. Adiponectin
3.5.2.1. Retinopathy. Adiponectin was signiﬁcantly elevated in patients
with diabetic retinopathy (n = 324) compared to patients without
diabetic retinopathy (n = 983) [SMD = 0.38; 95% CI = 0.25–0.51;
p b 0.00001; I2 = 0%] from three studies (Choe et al., 2013; Jung et al.,
2014; Pradeepa et al., 2015) (Supplementary Fig. G.1, Table 4). When
considering severity of retinopathy, adiponectin was not signiﬁcantly
different in patients with non-proliferative diabetic retinopathy (n =
221) compared to patients without diabetic retinopathy (n = 547)
[SMD = −0.51; 95% CI = −2.45 to 1.43; p = 0.61; I2 = 96%] from
four studies (Dossarps et al., 2014; Kato et al., 2008; Pradeepa et al.,
2015; Yilmaz et al., 2004) (Supplementary Fig. G.2, Table 4).
Adiponectin did not differ signiﬁcantly between patients with
non-proliferative diabetic retinopathy (n = 43) relative to patients
with proliferative diabetic retinopathy (n = 26) [SMD = −0.16; 95%
CI = −1.52 to 1.20; p = 0.82; I2 = 83%] from two studies (Kato
et al., 2008; Yilmaz et al., 2004) (Supplementary Fig. D.3, Table 4).
3.5.2.2. Nephropathy. Adiponectin was signiﬁcantly elevated in
patients with microalbuminuria (n = 92) relative to patients with
normoalbuminuria (n = 182) [SMD = 0.55; 95% CI = 0.29–0.81;
p b 0.0001; I2 = 0%] from four studies (Kato et al., 2008; Komaba
et al., 2006; Koshimura et al., 2004; Ran et al., 2010) (Supplementary
Table 2
Outcome deﬁnition details of studies included in systematic review.
Study Outcome Outcome deﬁnition Criterion Case (n) Controls (n)
Asakawa Retinopathy Retinopathy n/r 39 139
Nephropathy Microalbuminuria AER N30 mg/day 39 139
Neuropathy Peripheral neuropathy Signs/symptoms of peripheral neuropathy 47 135
Cha Nephropathy Macroalbuminuria AER ≥300 mg/day 76 40
Microalbuminuria AER 30–299 mg/day
Chan Nephropathy Microalbuminuria ACR N25 mg/mmol 34 12
Choe Nephropathy Microalbuminuria ACR N30 mg/g
AER N30 mg/day
245 448
Chung Nephropathy Microalbuminuria ACR 30–300 mg/g 113 50
Macroalbuminuria ACR N300 mg/g
Dossarps Retinopathy Retinopathy Fundoscopic examination 69 110
Fruehwald-Schultes Nephropathy Macroalbuminuria AER N300 mg/day 20 20
Microalbuminuria AER 30–300 mg/day
Fujita Nephropathy Microalbuminuria ACR 30–299 mg/g 18 19
Macroalbuminuria ACR ≥300 mg/g 16
Gottsater Neuropathy Parasympathetic R-R interval variation 24 58
Hanai Nephropathy Microalbuminuria ACR N25–355 mg/g (women); 17–250 mg/g (men) 158 344
Jung 2012 Neuropathy Cardiac autonomic neuropathy n/r 46 96
Jung 2014 Retinopathy Retinopathy Fundoscopic examination 18 135
Nephropathy Microalbuminuria AER 20–200 μg/min; ACR 30–300 mg/g 20 133
Macroalbuminuria AER N200 μg/min
ACR N300 mg/g
Neuropathy n/sp Self-assessment 87 66
Kato Retinopathy Simple Mild vascular changes 37 119
Pre-proliferative Ophthalmologist diagnosis 23
Proliferative Ophthalmologist diagnosis 11
Nephropathy Microalbuminuria ACR 30–300 mg/g 47 116
Macroalbuminuria ACR ≥300 mg/g 24
Overt nephropathy Serum creatinine ≥177 μmol/L 5
Komaba Nephropathy Microalbuminuria ACR 30–300 mg/g 93 86
Macroalbuminuria ACR ≥300 mg/g
Kopiesy Nephropathy Microalbuminuria AER 30–300 mg/day 20 60
Macroalbuminuria AER N300 mg/day
Koshimura Nephropathy Microalbuminuria ACR 30–300 mg/g 20 18
Macroalbuminuria ACR N300 mg/g
Matsuda Retinopathy Proliferative retinopathy Fundoscopic examination 191 263
Nephropathy Macroalbuminuria ACR 3.4–33.9 g/mol 83 148
Matsuda Neuropathy Nerve conduction velocity Motor and sensory nerve function n/r n/r
Pradeepa Retinopathy Proliferative retinopathy Retinal photography 81 487
Nephropathy Microalbuminuria n/r 143
Neuropathy n/sp n/r 138
Parveen Retinopathy Proliferative retinopathy Neovascularisation or pre-retinal haemorrhages 21 39
Non-proliferative retinopathy Microaneurysms, dot or blot haemorrhages,
hard or soft exudates or venous beadings
26
Ran Nephropathy Microalbuminuria ACR 30–300 mg/day 32 18
Macroalbuminuria ACR N300 mg/day
Saito Nephropathy Albuminuria stage I (no microalbuminuria) to V (under dialysis treatment) 204 76
Sari Retinopathy Proliferative retinopathy New vessels, conﬁrmed by angiography,
or previous treatment by photocoagulation
37 120
Nephropathy Microalbuminuria AER 30–300 mg/day 39 119
Macroalbuminuria AER N300 mg/day
Neuropathy Sensorial neuropathy Clinically and/or with electromyography 51 263
Autonomic neuropathy Orthostatic test
Swellam Retinopathy n/r n/sp 71 n/r
Nephropathy n/r Elevated serum creatinine level; stage V,
under dialysis treatment
76 n/r
Neuropathy n/r Self-assessment 110 n/r
Uckaya Retinopathy Proliferative retinopathy Vascular abnormalities 37 33
Wilson Nephropathy Albuminuria ACR ≥300 mg/day 10 10
Yilmaz Retinopathy Proliferative retinopathy Vascular abnormalities 44 30
Yilmaz Nephropathy Microalbuminuria Urinary protein N500 mg/day 45 40
ACR = albumin-creatinine ratio; AER = albumin excretion rate; mg = milligrams; n/r = not reported; mol = moles; g = grams; N = greater than; n/sp = not speciﬁed; μg =
micrograms; min = minute.
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macroalbuminuria (n = 64) relative to patients with normoalbuminuria
(n = 182) [SMD = 1.37; 95% CI = 0.78–1.97; p b 0.00001; I2 = 67%]
from four studies (Kato et al., 2008; Komaba et al., 2006; Koshimura et al.,
2004; Ran et al., 2010) conﬁrmed in a sensitivity analysis (Supplementary
Figs. I.1 and I.2; Table4). Adiponectinwas signiﬁcantly elevated inpatients
with macroalbuminuria (n = 64) relative to patients with microalbumi-
nuria (n = 92) [SMD = 0.87; 95%CI = 0.23, 1.51; p = 0.007; I2 = 67%]from four studies (Kato et al., 2008; Komaba et al., 2006; Koshimura et al.,
2004; Ran et al., 2010) conﬁrmed in a sensitivity analysis (Supplementary
Figs. J.1 and J.2; Table 4).
3.5.2.3. Neuropathy. Adiponectin was signiﬁcantly higher in patients
with diabetic neuropathy (n = 506) relative to patients without
diabetic neuropathy (n = 1010) [SMD = 0.25; 95% CI = 0.14–0.36;
p b 0.00001; I2 = 0%] from ﬁve studies (Choe et al., 2013; Jung et al.,
Table 3
Study quality scores using a modiﬁed Newcastle–Ottawa Scale.
Study Item Score
1 2 3 4 5 6
Asakawa 2001 **/** */– **/** */** **/** */* 9
Cha 2012 **/** */– **/** */* */* */* 7.5
Chan 2004 */** −/− **/** –/* */* */* 6
Choe 2013 **/** */– **/** –/* */* */* 7
Chung 2005 ***/** */– **/** **/* */– */* 8
Dossarps 2014 */** */* **/** –/* */– */* 6.5
Fruehwald-Schultes 1999 */* –/– **/** */* */** */* 6.5
Fujita 2006 **/* –/– **/** **/* */* */* 7
Gottsater 1999 **/* */– */** –/– –/* */* 5
Hanai 2010 */** */– **/** **/** **/** */* 9
Jung 2012 */* */– **/** */** **/** */* 8
Jung 2014 */* */– **/** **/** **/** */* 8.5
Kato 2008 **/* */– **/** **/** **/** */* 9
Komaba 2006 **/** */* **/** */* */– */– 7
Kopeisy 2011 */** –/* **/** –/** */– */* 6.5
Koshimura 2004 */* –/– */** –/– */* */* 4.5
Matsuda 2004 */* */– **/** */** */** */* 7.5
Matsuda 2004 **/* */– */** –/* –/** */* 6
Pradeepa 2014 **/** */* **/* –/* */– */* 6.5
Parveen 2013 */* –/* */* –/– */* */* 4.5
Ran 2010 **/* –/* **/** –/* */– */* 6
Saito 2007 **/** */* **/** */* */– */* 7.5
Sari 2010 **/** */* **/** –/* */– */* 7.5
Swellam 2009 */** */* */* */* */– */* 6
Uckaya 2000 **/*** –/* **/** –/* */** */* 8
Wilson 1999 –/* –/– */** –/– */* –/* 3.5
Yilmaz 2004 **/** –/* **/** –/** */** */* 8
Yilmaz 2008 **/*** –/* **/* */** */** */* 8.5
Scores were attributed by two reviewers, which were averaged to provide ﬁnal scores. Itemised scoring criteria are provided in Supplementary Material A.1.
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Fig. K, Table 4). The above results are summarised in Table 5.
3.5.3. Meta-regression
No relationship was found between BMI and duration of diabetes
and effect sizes, however a slight trend was evident with respect to
age (Supplementary Figs. L and M).
4. Discussion
4.1. Summary and highlight
Insulin-resistantT2DMaffectsasubstantialproportionof thepopulation,
and is associated with debilitating microvascular complications such as
retinopathy, nephropathy and neuropathy (Hammes, 2003). This investi-
gation suggests that adipocytokines are relevant to microvascular diseaseTable 4
Summary of heterogeneity of the studies included in the systematic review.
Adipocytokine Analysis # studies n
Leptin Micro vs Normo 6 901
Micro vs Macro 4 287
Macro vs Normo 6 406
DR vs No DR 3 380
Non DR vs no PDR 2 198
PDR vs Non PDR 2 74
PDR vs No DR 2 182
Neuro vs No Neuro 4 609
Adiponectin Micro vs Normo 4 274
Macro vs Normo 4 246
Macro vs Micro 4 156
DR vs No DR 3 1307
Non PDR vs No DR 4 768
Non PDR vs PDR 2 69
Neuro vs No Neuro 5 1516
Micro: microalbuminuria; Macro: macroalbuminuria; Normo: normoalbuminuria; DR: diaband represents the ﬁrst aggregated study to demonstrate the association
betweenincreased leptin levelsandnephropathy/neuropathy,andbetween
increased adiponectin levels and nephropathy/neuropathy/retinopathy.
4.2. Role of leptin and adiponectin in MV complications
Adipocytokines (also called adipokines) are adipose tissue-derived
molecules with hormone-like actions. Adipocytokines are established
metabolic regulators with functions in several other systems including
inﬂammation (Tian, Chang, Loh, & Hsieh, 2014). Leptin and adiponectin
are two of the most abundant adipocytokines. Adiponectin levels are
inversely related to the degree of adiposity (Cnop et al., 2003), whilst
leptin increases with adiposity (Ostlund, Yang, Klein, & Gingerich, 1996).
Diabetic microvascular complications are principally driven by
vascular inﬂammation, and there is strong evidence to suggest that
adipocytokines have important functions in vascular inﬂammationHeterogeneity χ2 (p value) Inconsistency I2 (%) Model
12.03 (0.03) 58 Random
1.62 (0.66) 0 Fixed
11.62 (0.04) 57 Random
21.45 (b0.0001) 91 Random
14.86 (0.0001) 93 Random
1.19 (0.28) 16 Fixed
10.25 (0.001) 90 Random
2.76 (0.43) 0 Fixed
2.78 (0.43) 0 Fixed
9.06 (0.03) 67 Random
9.19 (0.03) 67 Random
1.85 (0.4) 0 Fixed
23.29 (b0.00001) 96 Random
5.8 (0.02) 83 Random
2.54 (0.64) 0 Fixed
etic retinopathy; PDR: proliferative diabetic retinopathy; Neuro: neuropathy.
Table 5
Summary of results from the meta-analyses.
Adipokine Analysis n (total) SMD (95% CI) p value
Leptin Micro vs Normo 901 0.41 [0.14, 0.67] 0.0003
Macro vs Normo 406 0.68 [0.30, 1.06] 0.0004
Macro vs Micro 287 0.44 [0.20, 0.68] 0.0003
Neuro vs No Neuro 609 0.26 [0.07, 0.44] 0.008
DR vs No DR 380 0.49 [−0.38, 1.36] 0.27
Non PDR vs No DR 198 0.78 [−0.70, 2.25] 0.30
PDR vs Non PDR 74 0.41 [−0.11, 0.93] 0.12
PDR vs No DR 182 0.91 [−0.53, 2.36] 0.21
Adiponectin Micro vs Normo 274 0.55 [0.29, 0.81] b0.0001
Macro vs Normo 246 1.37 [0.78, 1.97] b0.00001
Macro vs Micro 156 0.87 [0.23, 1.51] 0.007
DR vs No DR 1,306 0.38 [0.25, 0.51] b0.00001
Non PDR vs No DR 768 −0.51 [−2.45, 1.43] 0.61
Non PDR vs PDR 69 −0.16 [−1.52, 1.20] 0.82
Neuro vs No Neuro 1,516 0.25 [0.14, 0.36] b0.00001
Micro: microalbuminuria; Macro: macroalbuminuria; Normo: normoalbuminuria; DR:
diabetic retinopathy; PDR: proliferative diabetic retinopathy; Neuro: neuropathy. Bold
indicates signiﬁcant result.
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vasculature, and adiponectin, has extensive vasculo-protective ac-
tions (Jamroz-Wiśniewska et al., 2014; Martínez-Martínez et al.,
2014; Nevelsteen et al., 2013).
4.3. Comparing and contrasting this investigation with the literature
Adiponectin is generally considered to be an anti-inﬂammatory
adipocytokine, and this is supported by a recent meta-analysis of over
3000 T2DM patients, where adiponectin was negatively correlated
with diabetic retinopathy (Fan et al., 2014). This result is in
contradiction to the present study. However, the population under
consideration in the present study is considerably more heteroge-
neous, compared to the population included in the meta-analysis by
Fan and colleagues, which was composed predominantly of Han
Chinese. In considering that adiponectin concentration is inﬂuenced
by genetic background, we postulate that our genetically diverse
study represents themore robust result andmay explain the disparate
ﬁndings (Morimoto et al., 2014). Furthermore, it may be reasonable to
hypothesise that adiponectin in fact plays no role in the pathophys-
iology of diabetic microvascular complications, and is increased in an
attempt to counteract leptin's deleterious effects or may have a novel
as yet unknown effect on diabetic microvascular complications
(Costacou & Orchard, 2008; Ebert & Fasshauer, 2011). Overall, cellular
and clinical evidence presents leptin and adiponectin as relevant and
important to diabetic microvascular complications as these compli-
cations are driven by a component of inﬂammation in pathways
which are directly affected by these adipocytokines.
Adiponectin levels differ in the presence of macrovascular versus
microvascular complications. Patients with macrovascular complica-
tion display low concentrations of plasma adiponectin levels (Boyle,
2007; Wang, Gao, Su, Xu, & Fu, 2015; Yazici et al., 2012), whereas it
has been reported that microvascular complications are associated
with increased circulating adiponectin levels (Frystyk, Tarnow,
Krarup Hansen, Parving, & Flyvbjerg, 2005). Atherosclerosis is an
essential aetiological component of macrovascular complications
(Fowler, 2011). The process of atherosclerosis appears to involve
the synergistic action of hyperglycaemia and hyperlipidaemia (Chait
& Bornfeldt, 2009). In an in vivo study, it was shown that diabetic pigs
develop atherosclerosis in presence of hyperlipidaemia, but not in its
absence, suggestive of a synergistic interaction between hyperlipid-
aemia and glycaemia in the progression of macrovascular complica-
tion (Gerrity, Natarajan, Nadler, & Kimsey, 2001). Thus, it could be
hypothesised that increased hyperlipidaemia, which is ultimately
involved in macrovascular complications, might play a role indecreasing circulating adiponectin. Interestingly, low plasma adipo-
nectin favours progression of atherosclerosis and vascular plaque
formation (Broedl et al., 2009; Yazici et al., 2012). Therefore, the
increased levels of circulating adiponectin observed in microvascular
complications (as evident in this meta-analysis) could result from a
compensatory mechanism to counter inﬂammatory processes that
occur as part of the pathophysiology of microvascular disease
complication, in the absence of macrovascular complications. In fact,
a mounting body of evidence supports that adiponectin exerts
vascular protective actions including anti-atherogenic effects (Broedl
et al., 2009; Iwaki et al., 2003; Yazici et al., 2012).
Despite this literature, there has been little direct examination of
the role of leptin and adiponectin in microvascular complications. We
identiﬁed several studies that suggest leptin and adiponectin are
relevant to these conditions (Asakawa et al., 2001; Cha et al., 2012;
Chan et al., 2004; Choe et al., 2013; Chung et al., 2005; Dossarps et al.,
2014; Fruehwald-Schultes et al., 1999; Fujita et al., 2006; Hanai et al.,
2010; Jung et al., 2012, 2014; Kato et al., 2008; Komaba et al., 2006;
Kopeisy et al., 2011; Koshimura et al., 2004; Matsuda, Kawasaki,
Inoue, et al., 2004;Matsuda, Kawasaki, Yamada, et al., 2004; Parveen &
Zia Qureshi, 2013; Pradeepa et al., 2015, Ran et al., 2010, Saito et al.,
2007; Sari et al., 2010; Swellam et al., 2009; Uckaya et al., 2000;
Wilson et al., 1998; Yilmaz et al., 2004, 2008). As this investigation
attests, these studies have proven to be heterogeneous in their
ﬁndings of associations between leptin and adiponectin and diabetic
microvascular complications. In light of this, we have attempted to
clarify these results by way of a systematic review and meta-analysis
and found leptin and adiponectin to be signiﬁcantly associated with
diabetic microvascular complications.
4.4. Limitations of included studies
We identiﬁed some limitations of the included studies. All
included studies were cross-sectional observational clinical studies.
These studies leave open the possibility of selection bias as no
randomisation was performed (recorded as part of the NOS).
Therefore associations drawn in cross-sectional studies do not imply
causation. Importantly, we did not exclude longitudinal studies from
our literature search. In order to properly identify causative agents or
assess the role of adipocytokines in microvascular complication
development, large prospective trials are needed.
Another potential source of heterogeneity is the use of medica-
tions by the patients in this cohort. Generally, medication use was
poorly reported and no instance exists where results (data relating to
leptin and adiponectin with respect to patients with and without
complications) were adjusted for medication use. Multiple co-mor-
bidities are common in people with diabetes and many of these
co-morbidities can be treated medically (e.g. ﬁbrates for hypertrigly-
ceridaemia) and these therapies are in addition to the many medical
treatments patients with diabetes already receive for the diabetes
itself (e.g. insulin, metformin or the glitazones). It is not known what
effect these adjunct therapies have on adipocytokine levels in the
blood in patients with microvascular complications.
Furthermore, several studies failed to report a method or criteria
for evaluating diabetes in patients recruited, even if the presence of
diabetes was part of the study inclusion criteria (Chan et al., 2004;
Fruehwald-Schultes et al., 1999; Jung et al., 2012, 2014; Uckaya et al.,
2000). This is important, as different countries have different
standards for diabetes deﬁnitions. In considering that the studies
included here were conducted in many different countries (e.g. Japan,
Korea, Germany, Turkey and Egypt), we may be grouping some
patients with poorly controlled diabetes together with patients with
well-controlled diabetes according the deﬁnitions set in this country
(Australia). Further to this, there was no direct assessment of possible
leptin resistance in these patients. This is extremely relevant to the
diabetes population as leptin resistance is a common ﬁnding in
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effects may be mitigated by adjusting results according to baseline
leptin levels, but this too was not performed in the studies included
for meta-analysis.
There was also limited reporting of inﬂammatory markers which
may be important in distinguishing the inﬂammatory effects of leptin
and adiponectin from classic pro-inﬂammatory cytokines. Moreover,
the duration of diabetes varied greatly and may have contributed to
heterogeneity, as the risk of developing these chronic complications
increases with longer diabetes duration. Finally, some studies were
generally small in size, and as they included only patients with
diabetes, the results may not be generalisable to patients with similar
microvascular morbidities independent of diabetes.
4.5. Limitations of this meta-analysis
Our meta-analysis has some limitations. This meta-analysis was
performed using aggregate data, and as suchwe did not have access to
all primary data to enable adjustment of adipokine levels to factors
strongly related to the risk of diabetic complications. However, we
performed meta-regression analyses using the study-level con-
founders of age, BMI and duration of diabetes, representing the
most important microvascular complication risk factors. No relation-
ship between BMI and duration of diabetes was evident, suggesting
that these study-level variables did not inﬂuence the effect size (SMD
between leptin or adiponectin levels in case and control groups). A
slight trend was evident with age: increasing age increased the effect
size, suggesting that in patients with advanced age, the effect size
(SMD between leptin or adiponectin levels in case and control groups)
would be greater. However, it has been shown that the age-dependent
changes in leptin and adiponectin levels are not very signiﬁcant
(Balaskó, Soós, Székely, & Pétervári, 2014).
In considering that leptin and adiponectin have been inconsis-
tently associated with MV complications (some reporting no
association, some reporting higher leptin or adiponectin to be
associated and some reporting lower leptin or adiponectin to be
associated), our study adds value to the literature in this area as a
succinct, synthesised report. We cannot conﬁrm whether the
association of leptin with nephropathy is independent of hyperten-
sion. Increased leptin has variously been reported with normotension,
hypertension and indeed may be elevated independent of hyperten-
sive status (Almeida-Pititto, Gimeno, Freire, Ribeiro-Filho, & Ferreira,
2006; Tsuda & Nishio, 2004). Importantly, leptin does not mediate
hypertension in human obesity and obesity is common amongst
patients with T2DM suggesting increased leptin in nephropathy is
occurring independently of hypertension (Brown, Meehan, & Gorden,
2015). However, to mitigate any potential effects, we attempted to
include blood pressure in the meta-regression. As speciﬁc systolic or
diastolic blood pressures were poorly reported by these studies, we
sought these data directly from authors however we received no
timely response. Other important sources of heterogeneity were
sample sizes of some of the analyses, and that we grouped together
results where adipocytokines were measured either in plasma or in
serum. Also, ethnic and gender differences may account for possible
bias in our results as we included studies from many racially and
genetically distinct populations. Finally, we cannot discount any age
or sex speciﬁc affects as possible sources of heterogeneity as for
example, leptin levels tend to be higher in females.
5. Conclusion
Overall, we sought literature that examined the association
between circulating levels of the adipocytokines leptin and adipo-
nectin and diabetic microvascular complications. Our analysis
revealed that higher leptin and adiponectin levels were associated
withmacro- andmicroalbuminuria and neuropathy. Further, elevatedadiponectin was also associated with retinopathy. This meta-analysis
represents the ﬁrst comprehensive quantitative assessment of
adipocytokines in diabetic microvascular complications, and the
results here could be translated into diagnostics, surveillance tools
or for risk prediction uses. This pool of participants is likely
underpowered to determine the inﬂuence of adipocytokines in
microvascular complication development, and therefore large pro-
spective studies are required to conﬁrm and validate these ﬁndings
independent of known risk factors and determine their causality.
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